G protein‐coupled receptors as anabolic drug targets in osteoporosis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pharmacology and Therapeutics

• Publication date

  2017-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pharmthera.2017.10.015PMID 29080701
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure of the full-length glucagon class B G protein-coupled receptor

  2017cited by this paper
• The quest for new drugs to prevent osteoporosis-related fractures

  2017cited by this paper
• TRV0109101, a G Protein-Biased Agonist of the µ-Opioid Receptor, Does Not Promote Opioid-Induced Mechanical Allodynia following Chronic Administration

  2017cited by this paper
• Phase-plate cryo-EM structure of a class B GPCR-G protein complex

  2017influential reference
• Abaloparatide Is an Anabolic, but Does It Spare Resorption?

  2017cited by this paper
• The quest for new drugs to prevent osteoporosis-related fractures.

  2017cited by this paper
• Superior Gains in Bone Mineral Density (BMD) and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide (TPTD) in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-label STRUCTURE Study

  2016cited by this paper
• Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures

  2016cited by this paper
• The role of the second extracellular loop of the adenosine A 1 receptor on allosteric modulator binding , signaling and cooperativity

  2016cited by this paper
• Amgen/UCB build on bone franchise with anti-sclerostin antibody

  2016cited by this paper
• Structural mechanism of ligand activation in human calcium-sensing receptor

  2016cited by this paper
• Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

  2016cited by this paper
• OP0100 Superior Gains in Bone Mineral Density and Estimated Strength at The Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of The Phase 3 Open-Label Structure Study

  2016cited by this paper
• Localization and function of the renal calcium-sensing receptor

  2016cited by this paper
• Regulation of bone metabolism by Wnt signals.

  2016cited by this paper
• A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density

  2015cited by this paper
• AP2 suppresses osteoblast differentiation and mineralization through down-regulation of Frizzled-1.

  2015cited by this paper
• Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.

  2015cited by this paper
• Coupling Signals between the Osteoclast and Osteoblast: How are Messages Transmitted between These Temporary Visitors to the Bone Surface?

  2015cited by this paper
• Actions of the small molecule ligands SW106 and AH-3960 on the type-1 parathyroid hormone receptor.

  2015cited by this paper
• Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy*

  2015cited by this paper
• PTH receptor-1 signalling—mechanistic insights and therapeutic prospects

  2015cited by this paper
• Control of Parathyroid Hormone Secretion by Extracellular Ca2

  2015cited by this paper
• Novel targets for the prevention of osteoporosis – lessons learned from studies of metabolic bone disorders

  2015cited by this paper
• Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics

  2015cited by this paper
• Novel EP4 Receptor Agonist‐Bisphosphonate Conjugate Drug (C1) Promotes Bone Formation and Improves Vertebral Mechanical Properties in the Ovariectomized Rat Model of Postmenopausal Bone Loss

  2015cited by this paper
• Osteoblast differentiation and survival: A role for A2B adenosine receptor allosteric modulators.

  2014cited by this paper
• Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit.

  2014cited by this paper
• Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts

  2014influential reference
• Bone Histomorphometry of Transiliac Paired Bone Biopsies After 6 or 12 Months of Treatment With Oral Strontium Ranelate in 387 Osteoporotic Women: Randomized Comparison to Alendronate

  2014cited by this paper
• Implications of Osteoblast-Osteoclast Interactions in the Management of Osteoporosis by Antiresorptive Agents Denosumab and Odanacatib

  2014cited by this paper
• Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond

  2014cited by this paper
• Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures

  2014cited by this paper
• Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case–control study in the CPRD

  2013cited by this paper
• Structural insights into the role of the Smoothened cysteine-rich domain in Hedgehog signalling

  2013influential reference
• Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism

  2013cited by this paper
• Structure of the human smoothened receptor 7TM bound to an antitumor agent

  2013cited by this paper
• Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders.

  2013cited by this paper
• Role of the calcium-sensing receptor in extracellular calcium homeostasis.

  2013cited by this paper
• Structure of the human smoothened receptor bound to an antitumour agent

  2013cited by this paper
• WNT signaling in bone homeostasis and disease: from human mutations to treatments

  2013cited by this paper
• Osteoclast-Derived Coupling Factors in Bone Remodeling

  2013cited by this paper
• LRP5 and LRP6 in development and disease.

  2013cited by this paper
• Noncanonical GPCR signaling arising from a PTH receptor–arrestin–Gβγ complex

  2013cited by this paper
• Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women.

  2013cited by this paper
• A comparison of parathyroid hormone‐related protein (1‐36) and parathyroid hormone (1‐34) on markers of bone turnover and bone density in postmenopausal women: The PrOP study

  2013cited by this paper
• Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.

  2013cited by this paper
• Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties

  2013cited by this paper
• Calcimimetic and calcilytic drugs

  2012cited by this paper
• Constitutive activation of smoothened leads to impaired developments of postnatal bone in mice

  2012cited by this paper
• Osteoblast and osteoclast crosstalks: from OAF to Ephrin.

  2012cited by this paper
• Structural Basis of Wnt Recognition by Frizzled

  2012cited by this paper
• Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor.

  2012cited by this paper
• Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression

  2012cited by this paper
• PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor.

  2012cited by this paper
• Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

  2012cited by this paper
• Estrogen and the skeleton.

  2012cited by this paper
• Ronacaleret, a calcium‐sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women

  2012cited by this paper
• The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice.

  2012cited by this paper
• Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

  2012cited by this paper
• Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.

  2012cited by this paper
• A2B Adenosine Receptor Promotes Mesenchymal Stem Cell Differentiation to Osteoblasts and Bone Formation in Vivo*

  2012cited by this paper
• Osteoblast extracellular Ca2+‐sensing receptor regulates bone development, mineralization, and turnover

  2011cited by this paper
• Trends in the exploitation of novel drug targets

  2011cited by this paper
• Disruption of PCP signaling causes limb morphogenesis and skeletal defects and may underlie Robinow syndrome and brachydactyly type B.

  2011cited by this paper
• Control of bone formation by the serpentine receptor Frizzled-9

  2011cited by this paper
• Profiling Insulin Like Factor 3 (INSL3) Signaling in Human Osteoblasts

  2011cited by this paper
• Retromer terminates the generation of cAMP by internalized PTH-receptors

  2011cited by this paper
• Gsα enhances commitment of mesenchymal progenitors to the osteoblast lineage but restrains osteoblast differentiation in mice.

  2011cited by this paper
• Adenosine receptor subtype expression and activation influence the differentiation of mesenchymal stem cells to osteoblasts and adipocytes

  2011cited by this paper
• The regulation of parathyroid hormone secretion and synthesis.

  2011cited by this paper
• Effect of cinacalcet on bone mineral density of the radius in hemodialysis patients with secondary hyperparathyroidism.

  2011cited by this paper
• The type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced bone loss by affecting osteoblast differentiation and bone formation.

  2011cited by this paper
• CB2 Cannabinoid Receptor Targets Mitogenic Gi Protein–Cyclin D1 Axis in Osteoblasts

  2010cited by this paper
• The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis.

  2010cited by this paper
• Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose.

  2010cited by this paper
• Strontium Ranelate Decreases Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclastic Differentiation In Vitro: Involvement of the Calcium-Sensing Receptor

  2010cited by this paper
• Membrane receptors: structure and function of the relaxin family peptide receptors.

  2010cited by this paper
• Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism.

  2010cited by this paper
• Implication of the calcium sensing receptor and the Phosphoinositide 3-kinase/Akt pathway in the extracellular calcium-mediated migration of RAW 264.7 osteoclast precursor cells.

  2010cited by this paper
• Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery

  2010cited by this paper
• Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants

  2009cited by this paper
• Sustained cyclic AMP production by parathyroid hormone receptor endocytosis.

  2009cited by this paper
• Functional Selectivity of Natural and Synthetic Prostaglandin EP4 Receptor Ligands

  2009cited by this paper
• Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate.

  2009cited by this paper
• Osteoblasts play key roles in the mechanisms of action of strontium ranelate

  2009cited by this paper
• The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion.

  2009cited by this paper
• Prostaglandin EP2 and EP4 receptor agonists in bone formation and bone healing: In vivo and in vitro evidence.

  2009cited by this paper
• The Calcium-sensing Receptor Is Involved in Strontium Ranelate-induced Osteoclast Apoptosis

  2009cited by this paper
• Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

  2009cited by this paper
• A β-Arrestin–Biased Agonist of the Parathyroid Hormone Receptor (PTH1R) Promotes Bone Formation Independent of G Protein Activation

  2009influential reference
• Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.

  2009cited by this paper
• Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate

  2008cited by this paper
• Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor.

  2008cited by this paper
• Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation.

  2008cited by this paper
• Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation

  2008cited by this paper
• Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro.

  2008cited by this paper
• Mutations in the Insulin‐Like Factor 3 Receptor Are Associated With Osteoporosis

  2008cited by this paper
• Bisphosphonates: mechanism of action and role in clinical practice.

  2008cited by this paper
• The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation.

  2007cited by this paper

• Novel SNP Combination for Predictive Osteoporotic Diagnosis

  2025cites this paper
• Oral delivery of teriparatide utilizing biocompatible transferrin-engineered MOF nanoparticles for osteoporosis therapy

  2025cites this paper
• Differential effects of structurally different lysophosphatidylethanolamine species on proliferation and differentiation in pre-osteoblast MC3T3-E1 cells

  2025cites this paper
• Transcriptional reprogramming during human osteoclast differentiation identifies regulators of osteoclast activity

  2024cites this paper
• 3D-printed bioink loading with stem cells and cellular vesicles for periodontitis-derived bone defect repair

  2024cites this paper
• SNPs in GPCR Genes and Impaired Osteogenic Potency in Osteoporotic Patient Lines-Based Study

  2024cites this paper
• Gallein but not fluorescein enhances the PGD2-stimulated synthesis of osteoprotegerin and interleukin-6 in osteoblasts: Amplification of osteoprotegerin/interleukin-6 by gallein.

  2024cites this paper
• Mechanistic advances in osteoporosis and anti‐osteoporosis therapies

  2023cites this paper
• GPR125 positively regulates osteoclastogenesis potentially through AKT-NF-κB and MAPK signaling pathways

  2022cites this paper
• Biased and allosteric modulation of bone cell-expressing G protein-coupled receptors as a novel approach to osteoporosis therapy.

  2021cites this paper
• Integration of 3D Structural and Sequence Features to Predict GPCR Ligand Binding

  2021cites this paper
• Sphingosine 1-phosphate and osteoporosis: pathophysiology and therapeutic aspects-a narrative review.

  2021cites this paper
• F2r negatively regulates osteoclastogenesis through inhibiting the Akt and NFκB signaling pathways

  2020cites this paper
• Ghrelin uses the GHS-R1a/Gi/cAMP pathway and induces differentiation only in mature osteoblasts. This ghrelin pathway is impaired in AIS patients

  2020cites this paper
• LncRNA‐mRNA expression profiles and functional networks in osteoclast differentiation

  2020cites this paper
• Phosvitin and its hydrolysate promote differentiation and inhibit TNF-ɑ induced inflammation in MC3T3-E1 cells via ERK and AKT pathways

  2019cites this paper
• The role of GPCRs in bone diseases and dysfunctions

  2019cites this paper
• Sphingolipid-mediated calcium signaling and its pathological effects.

  2018cites this paper